Drugs / Sofosbuvir/Ledipasvir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02638233 | Sep 2015 → Sep 2016 | chronic hepatitis C virus infection | Wilhelminenspital Vienna | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2013-05-02 | Gilead Sciences | Results Gilead Reports Interim Data From Phase 2 LONESTAR Study gilead.com ↗
In this study, 19/19 patients in the 12-week arm had a sustained virologic response four weeks after completing therapy (SVR4) |
| 2013-03-26 | Gilead Sciences | Results Gilead Announces Update on Phase 3 Study of Oral Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients gilead.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2013-05-02 | Gilead Sciences | Gilead Reports Interim Data From Phase 2 LONESTAR Study gilead.com ↗ |
| 2013-03-26 | Gilead Sciences | Gilead Announces Update on Phase 3 Study of Oral Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients gilead.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sofosbuvir/Ledipasvir | “In this non-interventional study patients with chronic hepatitis C, genotype 1, will be treated with Harvoni® (Sofosbuvir/Ledipasvir).” NCT02638233 ↗ |
| Route | Oral | “Subjects will receive sofosbuvir 400mg q.d p.o and ledipasvir 90 mg q.d p.o (FDC)” NCT02638233 ↗ |